Menu

Filtros : "Financiamento MMV" "QUÍMICA MÉDICA" Limpar

Filtros

Refine with date range

  • 1

1 - 2 (2 records)

  • Artigo de periodico

    Discovery and preclinical pharmacology of INE963, a potent and fast-acting blood-stage antimalarial with a high barrier to resistance and potential for single-dose cures in uncomplicated malaria (2022)

    Taft, Benjamin R.; Aguiar, Anna Caroline Campos

    Source: Journal of Medicinal Chemistry. Unidade: IFSC

    Subjects: ANTIMALÁRICOS, PLASMODIUM FALCIPARUM, PLANEJAMENTO DE FÁRMACOS, ANTIPARASITÁRIOS, MALÁRIA, BIOQUÍMICA, QUÍMICA MÉDICA

    Versão PublicadaAcesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      TAFT, Benjamin R. e AGUIAR, Anna Caroline Campos. Discovery and preclinical pharmacology of INE963, a potent and fast-acting blood-stage antimalarial with a high barrier to resistance and potential for single-dose cures in uncomplicated malaria. Journal of Medicinal Chemistry, v. 65, n. 5, p. 3798-3813, 2022Tradução . . Disponível em: https://doi.org/10.1021/acs.jmedchem.1c01995. Acesso em: 27 nov. 2025.

    • APA

      Taft, B. R., & Aguiar, A. C. C. (2022). Discovery and preclinical pharmacology of INE963, a potent and fast-acting blood-stage antimalarial with a high barrier to resistance and potential for single-dose cures in uncomplicated malaria. Journal of Medicinal Chemistry, 65( 5), 3798-3813. doi:10.1021/acs.jmedchem.1c01995

    • NLM

      Taft BR, Aguiar ACC. Discovery and preclinical pharmacology of INE963, a potent and fast-acting blood-stage antimalarial with a high barrier to resistance and potential for single-dose cures in uncomplicated malaria [Internet]. Journal of Medicinal Chemistry. 2022 ; 65( 5): 3798-3813.[citado 2025 nov. 27 ] Available from: https://doi.org/10.1021/acs.jmedchem.1c01995

    • Vancouver

      Taft BR, Aguiar ACC. Discovery and preclinical pharmacology of INE963, a potent and fast-acting blood-stage antimalarial with a high barrier to resistance and potential for single-dose cures in uncomplicated malaria [Internet]. Journal of Medicinal Chemistry. 2022 ; 65( 5): 3798-3813.[citado 2025 nov. 27 ] Available from: https://doi.org/10.1021/acs.jmedchem.1c01995

  • Artigo de periodico

    Design of proteasome inhibitors with oral efficacy in vivo against Plasmodium falciparum and selectivity over the human proteasome (2021)

    Xie, Stanley C. ; Aguiar, Anna Caroline Campos ; Guido, Rafael Victorio Carvalho

    Source: Proceedings of the National Academy of Sciences of the United States of America - PNAS. Unidade: IFSC

    Subjects: PLASMODIUM FALCIPARUM, PLANEJAMENTO DE FÁRMACOS, MALÁRIA, QUÍMICA MÉDICA

    PrivadoAcesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      XIE, Stanley C. e AGUIAR, Anna Caroline Campos e GUIDO, Rafael Victorio Carvalho. Design of proteasome inhibitors with oral efficacy in vivo against Plasmodium falciparum and selectivity over the human proteasome. Proceedings of the National Academy of Sciences of the United States of America - PNAS, v. 118, n. 39, p. e2107213118-1-e2107213118-9, 2021Tradução . . Disponível em: https://doi.org/10.1073/pnas.2107213118. Acesso em: 27 nov. 2025.

    • APA

      Xie, S. C., Aguiar, A. C. C., & Guido, R. V. C. (2021). Design of proteasome inhibitors with oral efficacy in vivo against Plasmodium falciparum and selectivity over the human proteasome. Proceedings of the National Academy of Sciences of the United States of America - PNAS, 118( 39), e2107213118-1-e2107213118-9. doi:10.1073/pnas.2107213118

    • NLM

      Xie SC, Aguiar ACC, Guido RVC. Design of proteasome inhibitors with oral efficacy in vivo against Plasmodium falciparum and selectivity over the human proteasome [Internet]. Proceedings of the National Academy of Sciences of the United States of America - PNAS. 2021 ; 118( 39): e2107213118-1-e2107213118-9.[citado 2025 nov. 27 ] Available from: https://doi.org/10.1073/pnas.2107213118

    • Vancouver

      Xie SC, Aguiar ACC, Guido RVC. Design of proteasome inhibitors with oral efficacy in vivo against Plasmodium falciparum and selectivity over the human proteasome [Internet]. Proceedings of the National Academy of Sciences of the United States of America - PNAS. 2021 ; 118( 39): e2107213118-1-e2107213118-9.[citado 2025 nov. 27 ] Available from: https://doi.org/10.1073/pnas.2107213118
  • 1

1 - 2 (2 records)

Digital Library of Intellectual Production of Universidade de São Paulo     2012 - 2025